南美洲和中美洲抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术（可裂解接头和不可裂解接头）、应用（血液癌、乳腺癌、卵巢癌、尿路上皮癌等）和分销渠道（医院）药房、零售药房和在线药房）
不断增加的 ADC 产品线推动南美洲和中美洲抗体药物偶联物市场
由于以下原因，各种生物制药公司正在开发 ADC人们对 ADC 作为有希望的癌症治疗方法的兴趣日益浓厚。诸如ImmunoGen, Inc.等公司； NBE-Therapeutics，Seagen Inc； ADC 疗法；默克公司；索伦托治疗公司；神话疗法；苏特罗生物制药公司；峰生物；再生元制药公司；阿萨纳生物科学公司；赛诺菲；纳维罗根公司；和 OBI Pharma 拥有处于不同开发阶段的 ADC。预计所开发的 ADC 的商业推出将显着扩大市场规模。
这些公司开发了一系列处于不同临床阶段和商业化管道的有前景的 ADC。管道中的 ADC 列表包括 Camidanlumab tesirine、ADCT-602、Zynlonta、ADCT-901、ADCT-701、ADCT-212、ADCT-601、Ladiratuzumab Vedotin、NBE-002、IMGN151、IMGN-632、IMGC 936、IMGN -151、OBI 999、R 992、NAV-001、MYTX-011、M1231、STI-6129、鱼雷、BCMA ADC、REGN5093-M114、ASN004、TR 1801 ADC。
公司还共享了与其各自产品相关的临床前数据。例如，2023 年 4 月，Mythic Therapeutics 公布了其 MYTX-011（cMET 靶向 ADC）的临床前数据。公布的数据包括 MYTX-011 旨在治疗多种 cMET+ 癌症的亮点。同样，在 2023 年 4 月举行的癌症研究协会年会上，Araris Biotech AG 公布了其抗 Nectin-4 和抗 HER2 ADC 的临床前数据。这两个 ADC 是使用该公司专有的链接器技术开发的。数据表明，在头对头体内研究中，与 FDA 批准的相应 ADC 相比，抗 Nectin-4 和抗 HER2 ADC 的抗肿瘤活性有所改善。因此，创新型 ADC 的兴起可能会在未来几年推动市场呈指数级增长。
南美洲和中美洲抗体药物偶联物市场概述
南美洲和中美洲的抗体药物偶联物市场分为巴西、阿根廷以及南美洲和中美洲的其他地区。该地区的市场增长主要归因于癌症筛查意识的提高。例如，巴西肠癌预防协会 (ABRAPRECI) 和结直肠癌预防和筛查计划已启动，以提高群众的认识。宣传活动和筛查计划的增长增加了对结肠镜检查服务的需求。此外，2020 年 12 月，法国诊断公司 HalioDx 与 Diagnosticos da America (DASA) 签署协议，在巴西分销其免疫评分结肠癌风险评估测试。免疫评分通过测量肿瘤部位的宿主免疫反应来帮助预测早期结肠癌复发的风险，这有助于规划治疗策略。根据协议条款，位于巴西圣保罗的 DASA 拥有该测试的独家经销权，通过 40 个实验室网络提供该测试。由于ADC针对特定癌细胞并向癌细胞释放有毒药物，预计该国不断增加的癌症病例将在未来提振市场。此外，根据阿根廷目前的结直肠癌筛查计划，由于发现了以前未诊断的疾病，预计结直肠癌的发病率很快就会增加。因此，这些因素可能有助于预测期内阿根廷抗体药物偶联物市场的进展。
南美洲和中美洲抗体药物偶联物市场收入和预测到 2030 年（百万美元）
南美洲和中美洲抗体药物偶联物市场细分
南美洲和中美洲抗体药物偶联物市场根据技术、应用、分销渠道和国家进行细分。
根据技术，南美洲和中美洲抗体药物偶联物市场抗体药物偶联物市场分为可裂解接头和不可裂解接头。到 2022 年，可裂解接头部分将占据更大的份额。
根据应用，南美和中美洲抗体药物偶联物市场抗体药物偶联物市场细分为血癌、乳腺癌、卵巢癌、尿路上皮癌和其他的。乳腺癌细分市场在 2022 年占据最大份额。
根据分销渠道，南美洲和中美洲抗体药物偶联物市场抗体药物偶联物市场分为医院药房、零售药房和在线药房。 2022 年，医院药房领域占据最大份额。
根据国家/地区，南美洲和中美洲抗体药物偶联物市场分为巴西、阿根廷、南美洲和中美洲其他地区。巴西在 2022 年主导南美洲和中美洲抗体药物偶联物市场。
辉瑞公司、罗氏公司、葛兰素史克公司、吉利德科学公司、阿斯利康公司、安斯泰来制药公司和武田制药有限公司是其中一些公司南美洲和中美洲抗体药物偶联物市场的领先公司。
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Antibody Drug Conjugates Market - Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market - South & Central America Market Analysis
5.1 South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
6. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology
6.1 Overview
6.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application
7.1 Overview
7.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Antibody Drug Conjugates Market - Country Analysis
9.1 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 South & Central America Antibody Drug Conjugates Market Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 South & Central America: Antibody Drug Conjugates Market, by Countries, 2022 and 2030 (%)
9.1.3.1 Brazil
9.1.3.1.1 Overview
9.1.3.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 Brazil: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Argentina
9.1.3.2.1 Overview
9.1.3.2.2 Argentina: Antibody Drug Conjugates Market, by Technology
9.1.3.2.3 Argentina: Antibody Drug Conjugates Market, by Application
9.1.3.2.4 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 Rest of South & Central America
9.1.3.3.1 Overview
9.1.3.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Takeda Pharmaceutical Co Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. South & Central America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market
List of Figures
Figure 1. South & Central America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. South & Central America Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. South & Central America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
7. Takeda Pharmaceutical Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America antibody drug conjugates market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in South & Central America antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution